NCT07665996 Girocitinib Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07665996 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 4 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07665996 is a hot trial to watch
Chronic Urticaria is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07665996 is notable because it evaluates Girocitinib in a Phase 1/2 design sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07665996 |
| Official title | A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines |
| Phase / status | Phase 1/2 / Not yet recruiting |
| Intervention | Girocitinib |
| Sponsor | Hangzhou Highlightll Pharmaceutical Co., Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | Time to first achievement of ≥1-point reduction from baseline in in-clinic Itch Severity Scale after first dose |
| Endpoint time frame | First dose up to day 2 |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The goal of this clinical trial is to evaluate the rapid onset characteristics of TLL-018 in moderate-to-severe CSU with inadequate response to second-generation H1 antihistamines. The main objectives are: To evaluate the rapid onset characteristics of TLL-018 in participants with moderate-to-severe chronic spontaneous urticaria. To evaluate the safety profile of TLL-018 in participants with moderate-to-severe chronic spontaneous urticaria. To evaluate the pharmacokinetic (PK) profile of TLL-018 in participants with moderate-to-severe chronic spontaneous urticaria. Participants will be randomly allocated at a 1:1:1 ratio to receive TLL-018 10 mg, TLL-018 20 mg, or placebo orally after meals.
Allocation is Randomized, masking is Quadruple, and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Time to first achievement of ≥1-point reduction from baseline in in-clinic Itch Severity Scale after first dose (First dose up to day 2) — Time from first dose until the first clinic assessment where a ≥1-point reduction from baseline in Itch Severity Scale (ISS, range 0-4; higher = worse itch) at in-clinic evaluation.
- Time to first ≥1-point reduction from baseline in in-clinic Hive Severity Scale after first dose (First dose up to day 2) — Time from first dose to the first in-clinic assessment with ≥1-point reduction from baseline on Hive Severity Scale (HSS, 0-4).
- Change from baseline in in-clinic Itch Severity Scale post first dose (First dose up to 8 hours post first dose) — Mean change from baseline of in-clinic ISS (0-4) at scheduled timepoints after first dose.
- Change from baseline in in-clinic Hive Severity Scale post first dose (First dose up to 8 hours post first dose) — Mean change from baseline of in-clinic Hive Severity Scale (0-4) at scheduled timepoints after first dosing.
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Girocitinib is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Hangzhou Highlightll Pharmaceutical Co., Ltd. is resolved to a normalized organization record in Hangzhou, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07665996 provides a focused lens on Chronic Urticaria development. Its value will be determined by whether Girocitinib can convert the current Phase 1/2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
